Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: “Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma”.
Tricia Kunst, Santhana Webb, Christina DeVisser, Christy Arrowood, Seth M. Steinberg +4 more